Patenting bioactive molecules from biodiversity: The Brazilian experience

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 2, 2010, Pages 145-157

  Nogueira, Renata Campos ^a   De Cerqueira, Harley Ferreira ^b   Soares, Milena Botelho Pereira ^a,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE SÃO PAULO   (Brazil)

^c HOSPITAL SÃO RAFAEL   (Brazil)

Author keywords

Biodiversity; Brazilian legislation; Chemical diversity; Drug development

Indexed keywords

ADENOREGULIN; ATRACURIUM; CAPTOPRIL; CURARE; DEHYDROEMETINE; DELTORPHIN; DERMORPHIN; EMETINE; HOMALANTHUS NUTANS EXTRACT; NATURAL PRODUCT; NEUROPEPTIDE; OCOTEA RODIAEI EXTRACT; OPIATE PEPTIDE; PILOCARPINE; PLANT EXTRACT; PROSTRATIN; RUPUNUNINE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

BIODIVERSITY; BIOLOGICAL ACTIVITY; BRAIN ISCHEMIA; BRAZIL; DRUG EFFECT; DRUG INDUSTRY; DRUG ISOLATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SOLUBILITY; ETHNOBOTANY; FROG; GEOGRAPHIC DISTRIBUTION; GLAUCOMA; GOVERNMENT; HEAD AND NECK CANCER; HEPATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LAW; NONHUMAN; PATENT; PHYLLOMEDUSA BICOLOR; PLANT BIOTECHNOLOGY; REVIEW; SKIN SECRETION; STRUCTURE ACTIVITY RELATION; XEROSTOMIA;

BIODIVERSITY; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; BRAZIL; CONSERVATION OF NATURAL RESOURCES; DRUG DISCOVERY; DRUG INDUSTRY; INTERNATIONAL COOPERATION; PATENTS AS TOPIC;

EID: 76149124532     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903555221     Document Type: Review

References (84)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477
2. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009;10:161-165
3. Lam KS. New aspects of natural products in drug discovery. Trends Microbiol 2007;15:279-288
4. Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006;7:265-277
5. Calderon LA, Silva-Jardim I, Zuliani JP, et al. Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria. J Braz Chem Soc 2009;20:1011-1023
6. Soejarto DD, Fong HH, Tan GT, et al. Ethnobotany/ethnopharmacology and mass bioprospecting: issues on intellectual property and benefit-sharing. J Ethnopharmacol 2005;22:15-22
7. Tedlock B. Indigenous heritage and biopiracy in the age of intellectual property rights. Explore 2006;2:256-259
8. Balbani AP, Silva DH, Montovani JC. Patents of drugs extracted from Brazilian medicinal plants. Expert Opin Ther Pat 2009;19:461-473
9. Kartal M. Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytother Res 2007;21:113-119
10. Harvey AL. Natural products as a screening resource. Curr Opin Chem Biol 2007;11:480-484
11. Myers N, Mittermeler RA, Mittermeler CG, et al. Biodiversity hotspots for conservation priorities. Nature 2000;403:853-858
12. Rosin A. Pilocarpine. A miotic of choice in the treatment of glaucoma has passed 110 years of use. Oftalmologia 1991;35:53-55
13. Gill RC. Provided source of Chondrodendron tomentosum for intocostrim (Squibb). In: White water and black magic. New York: Henry Holt; 1940
14. Cummins JA. Experience with 3057 administrations of curare to 232 psychotic patients treated with metrazol. Psychiatr Q 1943;17:655-670
15. Griffith HR, Johnson GE. The use of curare in anaesthesia. Anesthesiology 1942;3:418-419
16. King H. Curare alkaloids. Part V. Alkaloids of some Chondrodendron species and the origin of radix pareira bravae. J Chem Soc 1940;137:737-746
17. Raghavendra T. Neuromuscular blocking drugs: discovery and development. J R Soc Med 2002;95:363-367
18. Knight R. The chemotherapy of amoebiasis. J Antimicrob Chemother 1980;6:577-593
19. Chintana T, Sucharit P, Mahakittikun V, et al. In vitro studies on the sensitivity of local Entamoeba histolytica to anti-amoebic drugs. Southeast Asian J Trop Med Public Health 1986;17:591-594
20. Powell SJ, McLeod I, Wilmot AJ, Elsdon-Dew R. Dehydroemetine in amebic dysentery and amebic liver abscess. Am J Trop Med Hyg 1962;11:607-609
21. Ferreira SH. A bradykinin-potentiating factor (bpf) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965;24:163-169
22. Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-Potentiating peptides from Bothrops jararaca venon. Biochemistry 1970a;9:2583-2593
23. Ferreira SH, Greene LH, Alabaster VA, et al. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 1970b;24:379-380
24. Atkinson AB, Robertson JIS. Captopril in the treatment of hypertension and cardiac failure. Lancet 1979;2:836-839
25. Industrial Property Law. 1996. Available from: http://www.planalto.gov. br/ ccivil-03/Leis/L9279.htm. [Last accessed 28 September 2009]
26. Queiroz EF, Wolfender JL, Hostettmann K. Modern approaches in the search for new lead antiparasitic compounds from higher plants. Curr Drug Targets 2009;10:202-211
27. Slish DF, Ueda H, Arvigo R, Balick MJ. Ethnobotany in the search for vasoactive herbal medicines. J Ethnopharmacol 1999;66:159-165
28. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001;109:69-75
29. Koehm FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-220
30. Weissman KJ, Leadlay PF. Combinatorial biosynthesis of reduced polyketides. Nat Rev Microbiol 2005;3:925-936
31. Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 2003;7:402-4088
32. Keller TH, Pichota A, Yin Z. A practical view of druggability. Curr Opin Chem Biol 2006;10:357-361
33. Nogueira RC, Oliveira-Costa JF, De Sá MS, et al. Early toxicity screening and selection of lead compounds for parasitic diseases. Curr Drug Targets 2009;10:291-298
34. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003;43:218-227
35. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod 2004;67:2141-2153
36. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008;25:475-516
37. Leeds, JA, Schmitt, EK, Krastel P, et al. Recent developments in antibacterial drug discovery: microbe-derived natural products-from collection to the clinic. Expert Opin Investig Drugs 2006;15:211-226
38. Wolfender JL, Queiroz EF, Hostettmann K. The importance of hyphenated techniques in the discovery of new lead compounds from nature. Expert Opin Drug Discov 2006;1:237-260
39. Wolfender JL, Queiroz EF, Hostettmann K. Development and application of LC-NMR techniques to the identification of bioactive natural products. In: Colegate SM, Molyneux RJ, editors, Bioactive natural products: detection, isolation, and structural determination. 2nd edition. Boca Raton, New York: CRC. Press, Taylor & Francis Group; 2008. p. 143-190
40. Koehn FE. High impact technologies for natural products screening. Prog Drug Res 2008;65:177-210
41. Mishra KP, Ganju L, Sairam M, et al. A review of high throughput technology for the screening of natural products. Biomed Pharmacother 2008;62:94-98
42. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 2006;5:941-955
43. Varella MD. Tipologia de normas sobre controle do acesso aos recursos genéticos in Diversidade Biológica e Conhecimentos Tradicionais. Del Rey, Belo Horizonte, 2004
44. Provisional Measure No 2186-16/01. 2001. Avaliable from: http://www. planalto.gov.br/ccivil-03/mpv/2186-16. htm. [Last accessed 28 September 2009]
45. Vélez E. A Repartição de benefícios decorrentes do acesso à biodiversidade e ao conhecimento tradicional. São Paulo: Anais do XXV Seminário Nacional da Propriedade Intelectual, ABPI, 2005
46. Pria GD. A Repartição de benefícios decorrentes do acesso à biodiversidade e ao conhecimento tradicional. São Paulo: Anais do XXV Seminário Nacional da Propriedade Intelectual, ABPI, 2005
47. Nodari RO, Guerra MP. Biodiversidade: aspectos biológicos, geográficos, legais e éticos. Farmacognosia: da planta ao medicamento. 5a edition. Porto Alegre: UFRGS/UFSC, 2003
48. Directive 98/44/EC of the European Parliament and of the Council on the Legal Protection of Biotechnological Inventions. 1998. Available from: http://www.wipo.int/meetings/en/ doc-details.jsp?doc-id=1701. [Last accessed 28 September 2009]
49. INPI. Diretrizes para o Exame de Pedidos de Patente nas áreas de Biotecnologia e Farmacêutica. 2002. Available from: http://www.inpi.gov. br/menu-esquerdo/ patente/pasta-manual. [Last accessed 28 September 2009]
50. Technico-flor (S.A.). Cosmetic or food compositions containing copaiba. WO9400105; 1994
51. Amway Corporation. Skin whitener composition containing acerola cherry fermentate. US5747006; 1997
52. Yves Rocher biolog vegetale. Cosmetic or pharmaceutical composition containing an andiroba extract. US5958421; 1999
53. The Body Shop International. Cosmetic composition comprising cupuacu extract. GB2321644A; 1998
54. Asahi Foods Co., Ltd. Fat originating in cupuassu seed, process for producing the same and use thereof. EP00964765; 2000
55. Asahi Foods Co. Oil and fat derived from cupuacu, Theobroma grandiflorum seed, method for producing the same and its use. JP2001348593; 2001
56. Asahi Foods Co., Ltd. Fat originating in cupuassu seed, process for producing the same and use thereof. WO0125377; 2002
57. Schmidlehner M. Cupuaçu, a case of Amazonian self-assertion. Seedling, 2003. Available from: www.grain.org [Last accessed 14 September 2009]
58. Homma AKO. Biopirataria na Amazônia: como reduzir os riscos? Amazônia: Ci. & Desenv. 2005
59. Biopiracy in the Amazon. The cupuaçu case. 2009 Avalaible from: http://www. amazonlink.org/biopiracy/cupuacu.htm. [Last accessed 26 September 2009]
60. IP-Watch. Brazil fights to make case for international biodiversity protection. 2006. Available from: www.ip-watch.org [Last accessed 14 September 2009]
61. Vidal J. Biopirates who seek the greatest prizes. The guardian (U.K.), 15 November 2000. Available from: www.guardian.co. UK/print/0,3858,4090906,00html [Last accessed 14 September 2009]
62. Riley M, editor. Indigenous intellectual property rights: legal obstacles and innovative solutions. Walnut Creek, CA: Altana Press; 2004
63. Gorinsky C. Biologically active rupununines. US5569456; 1994
64. Gorinsky C. Biologically active rupununines. EP19940300726; 1996
65. Gorinsky C. Biologically active rupununines. US6048867; 1996
66. Cooper B, Plotkin MJ. Pharmaceuticals and frogs. The Oculusl 2006;52:54-69
67. Plotkin MJ. Medicine quest: in search of nature's healing secrets. New York: Penguin Group; 2000
68. Daly JW, Caceres J, Moni RW, et al. Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. Proc Natl Acad Sci USA 1992;89:10960-10963
69. Lazarus LH, Bryant SD, Cooper PS, Salvadori S. What peptides these deltorphins be. Prog Neurobiol 1999;57:377-420
70. Oeltgen PR, Kindy MS, Bishop PD. Method for treating ischemia. WO056766; 1999
71. Oeltgen PR, Kindy MS, Bishop PD. Method for treating ischemia. US6294519; 2001
72. Oeltgen PR, McClain CJ, Barve S, Bishop PD. Method for treating cytokine mediated hepatic injury. US6380164; 2002a
73. Oeltgen PR, Kindy MS, Sanchez, Bishop PD. Use of deltorphin a and/or dermorphin h for protection against ischemia and reperfusion injury. WO022152; 2002b
74. Oeltgen PR, Kindy MS, Sanchez, Bishop PD. Use of d-leu deltorphin for protection against ischemia and reperfusion injury. WO030450; 2002c
75. Secretariat of the Convention on Biological Diversity. 2000. Sustaining life on Earth: how the Convention on Biological Diversity promotes nature and human well-being. Avalaiable from: http://www.biodiv.org/doc/ publications/cbd-sustainen.pdf. [Last accessed 20 September 2009]
76. Prada P. Poisonous Tree Frog Could Bring Wealth to Tribe in Brazilian Amazon. The New York Times, 2006
77. Anvisa. Suco Noni e Vacina do Sapo Kambô têm propagandas suspensas. 2004. Avalaible from: http://www.anvisa.gov.br/ DIVULGA/noticias/ 2004/300404.htm [Last accessed 26 September 2009]
78. Ministério do meio ambiente. Secretaria do desenvolvimento sustentável. Projeto Kampô. Avaliable from: http://www.mma. gov.br/sitio/index.php?ido=conteudo. monta&idEstrutura=35 &idConteudo=3185. [Last accessed 26 September 2009]
79. Martins HM. Os Katukina e o kampô. Aspectos etnográficos da construção de um projeto de acesso a conhecimentos tradicionais. Universidade federal de Brasília, 2006
80. Lynn Y. 2004 Samoa's gift to the world. A new way to fight AIDS. Avalaible from: http://newscenter.lbl.gov/ [Last accessed 26 September 2009]
81. Turner DM. Natural product source material use in the pharmaceutical industry: the Glaxo experience. J Ethnopharmacol 1996;51:39-43
82. Schuster BG. A new integrated program for natural product development and the value of an ethnomedical approach. J Altern Complement Med 2001;7:61-72
83. Osava M. Biodiversity Goes to Market. 2007. Available from: http://ipsnews.net/ news.asp?idnews=36442 [Last accessed 14 September 2009]
84. The Federal Constitution, 1988. 1988. Available from: http://www.planalto.gov. br/ccivil-03/constituicao/ constitui%C3%A7ao.htm. [Last accessed 28 September 2009]